Investigational drug · Phase 3
albumin binding paclitaxel
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced Pancreatic Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Mar 24, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1,391
Any phase or sponsor naming "albumin binding paclitaxel"
First trial start
2022
Dec 20, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "albumin binding paclitaxel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced Pancreatic Cancer
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "albumin binding paclitaxel" as an intervention, largest first.
- Study of Nab-Paclitaxel in High Risk Early Breast CancerPivotal-lookingCompleted
GBG Forschungs GmbHAcademic, hospital or other
NCT01690702 · 2,886 participants · Start Sep 2012 · Primary completion Sep 30, 2018
Drug: Epirubicin; nab-Paclitaxel and 2 more · For: Breast Cancer
Sites: Frankfurt am Main, Germany
- A Study for the Adjuvant Treatment of Breast CancerPivotal-lookingRecruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT05420467 · 2,413 participants (planned) · Start Jul 10, 2022 · Primary completion Jul 10, 2027
Drug: Docetaxel; Carboplatin and 10 more · For: Breast Cancer
Sites: Hangzhou, China
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyActive, not recruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04266249 · 2,175 participants · Start Mar 13, 2020 · Primary completion Oct 31, 2027
Drug: Docetaxel; Nab-paclitaxel and 4 more · For: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8 and 6 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,008 sites in all
- A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation ModelPivotal-lookingNot yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07239271 · 2,000 participants (planned) · Start Nov 16, 2025 · Primary completion Dec 2027
Drug: The control group; Adaptive therapy of de-escalation and escalation based on imaging and molecular analysis for predicting response · For: Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy
- A Study for the Neoadjuvant Treatment of Breast CancerPivotal-lookingRecruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT05420454 · 1,576 participants (planned) · Start Jul 10, 2022 · Primary completion Jun 10, 2027
Drug: Docetaxel; Carboplatin and 9 more · For: Breast Cancer
Sites: Hangzhou, China
- Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCTPivotal-lookingRecruiting
Shengjing HospitalAcademic, hospital or other
NCT04137653 · 1,498 participants (planned) · Start Jul 19, 2021 · Primary completion Nov 30, 2025
Drug: nab-Paclitaxel+carboplatin; Paclitaxel+carboplatin · For: Breast Cancer
Sites: Shenyang, China
- A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT07865910 · 1,438 participants (planned) · Start Nov 30, 2026 · Primary completion Dec 30, 2030
Drug: Investigational drug: HLX37 dose1, IV, Q3W; PEMBROLIZUMAB (alone or when added to a regimen above) and 4 more · For: NSCLC (Advanced Non-small Cell Lung Cancer)
Sites: Hefei, China; Beijing, China; Chongqing, China · 16 sites in all
- A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01572038 · 1,436 participants · Start Jun 1, 2012 · Primary completion Sep 20, 2019
Drug: Docetaxel; Nab-paclitaxel and 3 more · For: Breast Neoplasms
Sites: Algiers, Algeria; La Rioja, Argentina; Rosario, Argentina · 299 sites in all
- Albumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast CancerNot yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT07899047 · 1,372 participants (planned) · Start Oct 2026 · Primary completion May 2030
Drug: Experimental Group; control group · For: Breast Cancer; HER2-negative Breast Cancer; Advanced Breast Cancer
Sites: Wuhan, China
- Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)Pivotal-lookingCompleted
GBG Forschungs GmbHAcademic, hospital or other
NCT01583426 · 1,229 participants · Start Jul 2012 · Primary completion Dec 2018
Drug: nab-Paclitaxel; Paclitaxel · For: Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS and 5 more
Sites: Berlin, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Protein corona guided albumin-binding paclitaxel nanoparticles for treatment of intracranial tumors.
Huo Y, Yu P, Wang T, et al. · Sci Rep 2026
- Pharmacokinetic evaluation of paclitaxel, albumin-binding paclitaxel, and liposomal-encapsulated albumin-binding paclitaxel upon gastric subserosal administration.
Lee Y, Park SM, Song IH, et al. · Front Pharmacol 2024
- Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study protocol for a multicenter, randomized phase 2 trial (T-CORE2201).
Imai H, Sakamoto Y, Takahashi S, et al. · BMC Cancer 2024
- Tislelizumab-induced cytokine release syndrome: the first case report and review of the literature.
Yin H, Diao Y, Zheng Z, et al. · Immunotherapy 2024
- Case Report: Intervention of radiotherapy improves the prognosis of rectal squamous cell carcinoma with high PD-L1 expression and enable patients to obtain NED status.
Qu F, Xiao L, Xiao Y, et al. · Front Immunol 2023
- A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Zhang F, Xu Y, Guo S, et al. · Ann Palliat Med 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.